*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

As of 08:11AM CEST. Market open. 3 yearsUI2Y.MUCategory average 5 yearsUI2Y.MUCategory average 10 yearsUI2Y.MUCategory average ...

Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

The global agricultural micronutrients market size was worth US$ 3.5 billion in 2020. The global agriculture micronutrient market is forecast to reach US$ 9.1 billion by 2030, growing at a compound ...

The global tissue imaging market was valued at US$ 14 billion in 2019. The global tissue imaging market is forecast to reach US$ 31 billion by 2030 by registering a compound annual growth rate of 8.6% ...

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in ...

Headlines,Wall Street analysts show strong enthusiasm for Merck, (NYSE:MRK),, with the average brokerage recommendation (ABR) ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with ...